SCHEDULE: Perceptive Advisors Cuts Lyra Therapeutics Stake to 7.8%

Perceptive Advisors and its affiliates have reduced their beneficial ownership in Lyra Therapeutics, Inc. to 7.8% through recent share sales.

Summary

• Perceptive Advisors LLC and its affiliates, including Joseph Edelman, now beneficially own 138,885 shares of Lyra Therapeutics, Inc. common stock, representing 7.8% of the outstanding shares.
• This ownership is based on 1,774,882 outstanding shares as of November 7, 2025, as reported by Lyra Therapeutics in its Form 10-Q.
• Perceptive Life Sciences Master Fund, Ltd. holds 124,859 shares (7.0%), and Perceptive LS (A), LLC holds 14,026 shares (0.8%).
• Since the filing of Amendment No. 7 on November 10, 2025, the reporting persons have sold a total of 45,875 shares of Lyra Therapeutics common stock.
• Sales occurred on November 11, 2025 (5,320 shares at a weighted average price of $4.3146), November 12, 2025 (8,745 shares at a weighted average price of $4.0594), and November 13, 2025 (31,810 shares at a weighted average price of $3.9001).

Sentiment

Score: 3

Explanation: The sentiment is negative due to a significant institutional investor reducing its stake in the company, especially as the sales occurred at progressively lower prices over several days. This suggests a lack of confidence or a strategic divestment.

Negatives

• A significant institutional investor, Perceptive Advisors, has reduced its stake in Lyra Therapeutics, selling 45,875 shares.
• The sales occurred at progressively lower weighted average prices: $4.3146 on November 11, $4.0594 on November 12, and $3.9001 on November 13, indicating a declining market price during the selling period.
• The reduction in ownership from a prominent life sciences investor could signal a loss of confidence or a strategic shift away from the company.

Industry Context

The reduction of a significant stake by a specialized life sciences investor like Perceptive Advisors in a biotechnology company such as Lyra Therapeutics could reflect a broader re-evaluation of portfolio holdings within the sector, potentially driven by company-specific developments or shifts in market sentiment towards early-stage biopharma assets.

Stakeholder Impact

• Shareholders: The reduction in a significant institutional stake could lead to negative market perception and potential downward pressure on the stock price.
• Company Management: May face increased scrutiny regarding company performance or strategic direction if a major investor is divesting.

Key Dates

Recommendation

The significant reduction in stake by a prominent institutional investor like Perceptive Advisors, coupled with sales occurring at declining prices, signals a potential lack of confidence in Lyra Therapeutics' near-term prospects. This action by a sophisticated investor often precedes further downward pressure on the stock, suggesting that current shareholders might consider divesting to mitigate potential losses.

Keywords

Lyra Therapeutics, Perceptive Advisors, Schedule 13D/A, Share Sales, Beneficial Ownership, Institutional Investor, Biotechnology, Healthcare, Equity Stake